Buckstein Rena, Chodirker Lisa, Yee Karen W L, Geddes Michelle, Leitch Heather A, Christou Grace, Banerji Versha, Leber Brian, Khalaf Dina, St-Hilaire Eve, Finn Nicholas, Nevill Thomas, Keating Mary-Margaret, Storring John, Parmentier Anne, Thambipillai Aksharh, Tang Derek, Westcott Christopher, Cameron Chris, Spin Paul
Division of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
Department of Medicine, University of Toronto, Toronto, Canada.
Leuk Lymphoma. 2023 Mar;64(3):651-661. doi: 10.1080/10428194.2022.2156793. Epub 2023 Jan 6.
Many patients with lower-risk myelodysplastic syndromes (LR MDS) require long-term red blood cell (RBC) transfusions to manage anemia. The consequences of RBC transfusions in LR MDS with ring sideroblasts (LR MDS-RS) are not well known. We estimated the association between cumulative RBC dose density and clinical and patient-reported outcomes using data from the MDS-CAN registry for patients enrolled between January 2008 and December 2018. Outcomes included overall survival, hospitalization, and health-related quality of life (HRQoL). A total of 145 enrolled patients with LR MDS and RS ≥5% had a median follow-up time of 27.1 months; 45 had no transfusions during follow-up, 51 had <1 transfusion per month, and 49 had ≥1 transfusion per month. The cumulative density of RBC transfusions was associated with significantly greater mortality, hospitalization, and inferior HRQoL, suggesting that exposure to RBC transfusion may constitute a significant treatment burden in patients with LR MDS-RS.
许多低危骨髓增生异常综合征（LR MDS）患者需要长期输注红细胞（RBC）来治疗贫血。RBC输注对伴有环形铁粒幼细胞的LR MDS（LR MDS-RS）患者的影响尚不清楚。我们使用2008年1月至2018年12月期间登记在MDS-CAN中的患者数据，估计了累积RBC剂量密度与临床及患者报告结局之间的关联。结局包括总生存期、住院情况以及健康相关生活质量（HRQoL）。共有145例登记的LR MDS且环形铁粒幼细胞≥5%的患者，中位随访时间为27.1个月；45例患者在随访期间未接受输血，51例患者每月输血次数<1次，49例患者每月输血次数≥1次。RBC输注的累积密度与显著更高的死亡率、住院率以及较差的HRQoL相关，这表明接受RBC输血可能给LR MDS-RS患者带来显著的治疗负担。
